2022 Conference on Retroviruses and Opportunistic Infections (CROI 2022) is being held virtually on 12-16 February 2022.
Gilead Sciences presented cumulative 5-year results from two Phase 3 studies of Biktarvy in treatment-naïve adults; data about the in vitro activity of Veklury against ten SARS-CoV-2 variants, including Omicron; and Phase 2/3 interim data evaluating the safety, tolerability and clinical outcomes of Veklury in pediatric patients with COVID-19:
- Biktarvy® demonstrates high efficacy and durable viral suppression at five years, in treatment-naïve adults
- Veklury® (remdesivir) retains antiviral activity against Omicron, Delta and other emergent SARS-CoV-2 variants in multiple in vitro studies
- Phase 2/3 interim data evaluating the safety, tolerability and clinical outcomes of Veklury® (remdesivir) in pediatric patients with COVID-19 presented at CROI 2022
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.